Maarten van Hessen

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction

Kieran F. Docherty, Pardeep S. Jhund, Brian Lee Claggett, João Pedro Ferreira et autres

Importance: Sodium glucose cotransporter 2 inhibitors reduce morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Clinicians may find estimates of the projected long-term benefits of sodium glucose cotransporter 2 inhibitors a helpful addition to clinical trial results …

gb, us, fr, se, dk, au, ar, pl (code pays fourni par la source)

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across eighteen countries

Marijke Linschoten, Alicia Uijl, Astrid Schut, C E M Jakob et autres

Abstract Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Method and results We used …

nl, de, gb, ch, sa, be, ru (code pays fourni par la source)

Early Invasive Versus Selective Strategy for Non–ST-Segment Elevation Acute Coronary Syndrome

Niels Hoedemaker, Peter Damman, Pier Woudstra, Alexander Hirsch et autres

BACKGROUND: The ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes) trial compared early invasive strategy with a selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and an elevated cardiac troponin T. No long-term benefit of an early …

nl (code pays fourni par la source)

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

Sean D. Pokorney, Jonathan Paul Piccini, Susanna R. Stevens, Manesh R. Patel et autres

BACKGROUND: Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for …

us, de, au, gb (code pays fourni par la source)

The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial

Matthew Aaron Cavender, Charles Michael Gibson, Eugene Braunwald, Stephen D. Wiviott et autres

AIMS: Rivaroxaban reduces cardiovascular death, myocardial infarction (MI), or stroke in patients following acute coronary syndrome (ACS). We aimed to characterize the specific effects of rivaroxaban on the size and type of MI. METHODS: The Anti-Xa Therapy to Lower Cardiovascular Events in …

us, ar, nl (code pays fourni par la source)

RIVAROXABAN REDUCES SPONTANEOUS AND LARGE MYOCARDIAL INFARCTIONS: FINDINGS FROM THE ATLAS ACS 2 – TIMI 51 TRIAL

Matthew Aaron Cavender, Eugene Braunwald, Charles Michael Gibson, Stephen D. Wiviott et autres

us (code pays fourni par la source)